Organisation paid for research Program year 2025 Source: CMS Open Payments

Boston University

Neither a doctor nor a teaching hospital

Research payments

$5,658,958

221 payments

Through program year 2025, Boston University is reported as receiving $5,658,958 in research payments, across 221 payments.

By program year

7 rows
Year Kind Amount Payments
2025 Research $892,229 33
2024 Research $771,555 38
2023 Research $1,028,999 31
2022 Research $399,275 6
2021 Research $1,522,325 60
2020 Research $829,491 45
2019 Research $215,085 8

Breakdown

Who paid Research payments · program years 2019–2025
  1. Alnylam Pharmaceuticals Inc. $4,726,453 207 payments
  2. Pfizer Inc. $746,625 9 payments
  3. Vertex Pharmaceuticals Incorporated $165,000 1 payment
  4. Geistlich Pharma, North America, Inc. $15,000 1 payment
  5. E.R. Squibb & Sons, L.L.C. $3,531 1 payment
  6. Takeda Pharmaceuticals U.S.A., Inc. $2,184 1 payment
  7. Neurocrine Biosciences, Inc. $165 1 payment
Studies the money was for Research payments · program years 2019–2025
  1. APOLLO-B: A Phase 3, Randomized, Double-blind, Placebo-controlled Multicenter Study to Evaluate the Efficacy and Safety of Patisiran in Patients With Transthyretin Amyloidosis With Cardiomyopathy (ATTR Amyloidosis With Cardiomyopathy) $1,244,439 43 payments
  2. Impact of Physical Therapy on Functional Performance and Joint Mechanics in Knee Osteoarthritis in Lab Assessments and Real World Data Collected By Digital Measures $700,000 2 payments
  3. HELIOS-A: A Phase 3 Global, Randomized, Open-label Study to Evaluate the Efficacy and Safety of ALN-TTRSC02 in Patients With Hereditary Transthyretin Amyloidosis (hATTR Amyloidosis) $487,687 31 payments
  4. Expanded Access Protocol to Provide Patisiran to Patients With Transthyretin-mediated Amyloidosis (ATTR Amyloidosis) With Cardiomyopathy $478,194 7 payments
  5. APOLLO-B: A Study to Evaluate Patisiran in Participants With Transthyretin Amyloidosis With Cardiomyopathy (ATTR Amyloidosis With Cardiomyopathy) $467,048 21 payments
  6. The Study of an Investigational Drug, Patisiran (ALN-TTR02), for the Treatment of Transthyretin (TTR)-Mediated Amyloidosis in Patients Who Have Already Been Treated With ALN-TTR02 (Patisiran) $430,595 30 payments
  7. A Phase 3 Randomized, Double-Blind, Placebo-Controlled Multicenter Study to Evaluate the Efficacy and Safety of Patisiran in Patients with Transthyretin Amyloidosis with Cardiomyopathy (ATTR amyloidosis with cardiomyopathy) $318,692 2 payments
  8. An Open-Label Extension Study to Assess the Safety and Efficacy of Vutrisiran in Patients with Transthyretin Amyloidosis with Cardiomyopathy (ATTR Amyloidosis with Cardiomyopathy) $303,966 7 payments
  9. HELIOS-B: A Study to Evaluate Vutrisiran in Patients With Transthyretin Amyloidosis With Cardiomyopathy $295,853 42 payments
  10. Expanded Access Protocol to Provide Patisiran to Patients With Transthyretin-mediated Amyloidosis With Cardiomyopathy $218,887 6 payments

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.

Provenance

Source: CMS Open Payments · through program year 2025

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record